MicroRNAs have emerged as crucial regulators of cardiac homeostasis and remodeling in various cardiovascular diseases. We previously demonstrated that miR-221 regulated cardiac hypertrophy in vitro. In the present study, we demonstrated that the cardiac-specific overexpression of miR-221 in mice evoked cardiac dysfunction and heart failure. The lipidated form of microtubule-associated protein 1 light chain 3 was significantly decreased and sequestosome 1 was accumulated in cardiac tissues of transgenic (TG) mice, indicating that autophagy was impaired. Overexpression of miR-221 in vitro reduced autophagic flux through inhibiting autophagic vesicle formation. Furthermore, mammalian target of rapamycin (mTOR) was activated by miR-221, both in vivo and in vitro. The inactivation of mTOR abolished the miR-221-induced inhibition of autophagy and cardiac remodeling. Our previous study has demonstrated that cyclin-dependent kinase (CDK) inhibitor p27 was a direct target of miR-221 in cardiomyocytes. Consistently, the expression of p27 was markedly suppressed in the myocardia of TG mice. Knockdown of p27 by siRNAs was sufficient to mimic the effects of miR-221 overexpression on mTOR activation and autophagy inhibition, whereas overexpression of p27 rescued miR-221-induced autophagic flux impairment. Inhibition of CDK2 restored the impaired autophagic flux and rescued the cardiac remodeling induced by either p27 knockdown or miR-221 overexpression. These findings reveal that miR-221 is an important regulator of autophagy balance and cardiac remodeling by modulating the p27/CDK2/mTOR axis, and implicate miR-221 as a therapeutic target in heart failure. Cell Death and Differentiation ( Heart failure is the ultimate outcome of various cardiovascular diseases and is a leading cause of morbidity and mortality worldwide. Although drugs and other therapies have been developed for the management of heart failure, its 5-year mortality rate remains high.1 In response to myocardial stresses, the heart initially compensates with cardiomyocyte hypertrophy. Under prolonged stress, the heart undergoes irreversible cardiac remodeling, which finally results in cardiac decompensation and subsequent heart failure. The process of pathological cardiac remodeling involves the dysregulation of many coding and non-coding genes; however, not all of these genes have been well characterized.MicroRNAs (miRNAs) are endogenous small non-coding RNA molecules that posttranscriptionally regulate the degradation and/or translation of their target genes.2 A large body of evidence indicates that miRNA-mediated gene regulation has important roles in the control of cardiac homeostasis and pathological remodeling.3-8 We previously found that miR-221 is significantly upregulated in patients with hypertrophic cardiomyopathy (HCM) and in a mouse model of cardiac hypertrophy and heart failure induced by pressure overload. The in vitro overexpression of miR-221 alone is sufficient to increase the size of cardiomyocytes, accompanied by enhanced expression levels of...
ACE2 appears to counterbalance the vasopressor effect of angiotensin I converting enzyme (ACE) in the reninangiotensin system. We hypothesized that ACE2 polymorphisms could confer a high risk of hypertension and have an impact on the antihypertensive response to ACE inhibitors. The hypothesis was tested in two casecontrol studies and a clinical trial of 3,408 untreated hypertensive patients randomized to Atenolol, Hydrochlorothiazide, Captopril, or Nifedipine treatments for 4 weeks. ACE2 rs2106809 T allele was found to confer a 1.6-fold risk for hypertension in women (95% confidence interval (CI), 1.132.06), whereas when combined with the effect of the ACE DD genotype, the risk was 2.34-fold (95% CI, 1.754.85) in two independent samples. The adjusted diastolic blood pressure response to Captopril was 3.3 mm Hg lower in ACE2 T allele carriers than in CC genotype carriers (P=0.019) in women. We conclude that the ACE2 T allele confers a high risk for hypertension and reduced antihypertensive response to ACE inhibitors.
The major epigenetic features of mammalian cells include DNA methylation, posttranslational histone modifications and RNA-based mechanisms including those controlled by small non-coding RNAs (microRNAs (miRNAs)). An important aspect of epigenetic mechanisms is that they are potentially reversible and may be influenced by nutritional-environmental factors and through gene-environment interactions. Studies on epigenetic modulations could help us understand the mechanisms involved in essential hypertension and further prevent it's progress. This review is focused on new knowledge on the role of epigenetics, from DNA methylation to miRNAs, in essential hypertension.
This is the first population-based prospective cohort study exploring the ovarian aging process in Chinese women. A large sample size and long follow-up duration were achieved. Detailed analysis of data obtained from this cohort will be provided in future reports.
This phase II clinical trial compared the efficacy and safety of two types of treatment in patients with non-small-cell lung cancer (NSCLC) who had previously been treated with chemotherapy. Patients diagnosed with NSCLC (with either measurable or evaluable lesions) and had been treated with chemotherapy were eligible for this study. They were randomly assigned to two groups. The DOCp53 group received trans-tracheal Adp53 injection (1 × 10(12) vp dosage) on day 1 and day 8, as well as docetaxel at 75 mg m(-2) on day 2. The DOC group only received docetaxel at 75 mg m(-2) on day 1. Patients in each group received treatment for two cycles before reevaluation. Between February 2005 and December 2006, 40 patients were recruited for this study. In all, 19 of them were assigned to the DOCp53 group and 21 were assigned to the DOC group. After a mean follow-up of 12 months, the median survival time (MST) was 7.7 months (95% CI, 4.53 to 10.84) for patients in the DOCp53 group and 5.9 months (95% CI, 4.11 to 7.68) in the DOC group (P = 0.44, log-rank test). In the DOCp53 group, two patients with diffuse metastatic disease of lung had partial response (PR) in addition to eight with stable disease (SD). No PR and 13 SD were observed in the DOC group. Toxic reactions that could be attributed to the Adp53 vector were transient fever and limited hemoptysis. For patients with relapsed NSCLC, trans-tracheal injection of Adp53 in addition to docetaxel did not improve overall survival or efficacy. However, direct trans-tracheal injection of Adp53 proved to be a safe procedure, with tolerable levels of toxicity.
References1 van Iersel CA, van de Velden HVN, Kusters CDJ et al. Prognostic factors for a subsequent basal cell carcinoma: implications for followup. Br J Dermatol 2005; 153:1078-9. 2 Ramachandran S, Lear JT, Ramsay H et al. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype. Cancer Epidemiol Biomarkers Prev 1999; 8:61-7. 3 Ramachandran S, Fryer AA, Lear JT et al. Basal cell carcinoma: tumor clustering is associated with increased accrual in high-risk subgroups. Cancer 2000; 89:1012-18. 4 Lear JT, Heagerty AHM, Smith A et al. Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of next cutaneous basal cell carcinoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.